ReviewThe journal of headache and pain2019
Identifying and managing refractory migraine: barriers and opportunities?
Review in The journal of headache and pain, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Trial
- Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: randomized controlled trial.BMJ (Clinical research ed.) · 2021Trial
- Article
- Longitudinal assessment of migraine burden in resistant and refractory migraine - Data from the prospective REFINE study.The journal of headache and pain · 2025Article
- Resistant and refractory migraine - two different entities with different comorbidities? Results from the REFINE study.The journal of headache and pain · 2024Observational
- The Nursing Role in the Management of Medication Overuse Headache: Realities and Prospects.Brain sciences · 2024Review
- Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study.Journal of neurology · 2024Observational
- Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: REVIEW, an observational, multi-site, US-based study.The journal of headache and pain · 2024Observational
- Pulsed Radiofrequency Neuromodulation of the Greater Occipital Nerve for the Treatment of Headache Disorders in Adults: A Systematic Review.Canadian journal of pain = Revue canadienne de la douleur · 2024Article
- NOVEL APPROACHES IN DRUG TREATMENT OF MIGRAINES.Acta clinica Croatica · 2023Review
- Late Response to Anti-CGRP Monoclonal Antibodies in Migraine: A Multicenter Prospective Observational Study.Neurology · 2023Observational
- Algorithm-based approach to headache.Journal of family medicine and primary care · 2023Review
- Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17-30 months.The journal of headache and pain · 2023Article
- Breaking the cycle: unraveling the diagnostic, pathophysiological and treatment challenges of refractory migraine.Frontiers in neurology · 2023Review
- Rate and Predictors of Intractable Status Migrainosus among Patients Aged 13-18 Years.The Neurohospitalist · 2023Article
- Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis.The journal of headache and pain · 2022Article
- Screening for Copy Number Variations of the 15q13.3 Hotspot inCurrent issues in molecular biology · 2021Article
- Refractory migraine profile in CGRP-monoclonal antibodies scenario.Acta neurologica Scandinavica · 2021Article
- Approach to Pediatric Intractable Migraine.Current neurology and neuroscience reports · 2021Review
- Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).The journal of headache and pain · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The term refractory migraine has been used to describe persistent headache that is difficult to treat or fails to respond to standard and/or aggressive treatments. This subgroup of migraine patients are generally highly disabled and experience impaired quality of life, despite optimal treatments. Several definitions and criteria for refractory migraine have been published, but as yet, an accepted or established definition is not available. This article reviews the published criteria and proposes a new set of criteria. The epidemiology, pathophysiology and management options are also reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.